Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
FDA lifted clinical hold on ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS)
Covered in this story
Call it yourself
No calls on $AARD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Aardvark Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.